肿瘤防治研究2023，Vol.50Issue(12)：1232-1236,5.DOI:10.3971/j.issn.1000-8578.2023.23.1022
《2023 CSCO非小细胞肺癌诊疗指南》罕见靶点诊疗更新
Diagnostic and Therapeutic Strategy Updates of Rare Oncogenic Mutations in Chinese Society of Clinical Oncology Guidelines on Diagnosis and Treatment of Non-small Cell Lung Cancer(2023 Edition)
摘要
Abstract
The Chinese Society of Clinical Oncology(CSCO)issued the new version of the guidelines on diagnosis and treatment of NSCLC in April 2023.The new version updated the diagnostic and therapeutic strategy of rare oncogenic mutations,including ROS1 fusion,BRAF V600E mutation,NTRK fusion,MET exon 14 skipping mutation,RET fusion,and EGFR exon 20 insertion mutation,in NSCLC.This review will interpret the most important updates in the guidelines 2023 regarding the diagnosis as well as first-line and post-line therapies of these rare oncogenic mutations.关键词
非小细胞肺癌/罕见靶点/诊疗/指南更新/中国临床肿瘤学会Key words
NSCLC/Rare oncogenic mutations/Diagnosis and therapy/Guidelines updates/CSCO分类
医药卫生引用本文复制引用
李营歌,董熠,余舒阳,文英美,宋启斌,姚颐..《2023 CSCO非小细胞肺癌诊疗指南》罕见靶点诊疗更新[J].肿瘤防治研究,2023,50(12):1232-1236,5.基金项目
Natural Science Foundation of Hubei Province(No.2022CFB114)湖北省自然科学基金(2022CFB114) （No.2022CFB114）
